Study finds escitalopram beats agomelatine, duloxetine in preventing depression relapse

A large analysis has found that escitalopram is the most effective antidepressant for preventing relapse in patients recovering from depression. The study, which involved nearly 10,000 individuals prescribed various medications over a year, revealed that escitalopram outperformed other common antidepressants, including agomelatine and duloxetine, in keeping symptoms at bay.

This research, published in The Lancet Psychiatry, comes at a critical time as depression continues to affect around one in six people in the UK. With the right treatment, many can recover, but relapses remain a significant concern. Current medical guidelines suggest that patients stay on antidepressants for at least six months after symptoms improve to reduce the risk of relapse, and then gradually taper off their medication. The findings emphasize the importance of maintaining effective treatment plans to help prevent recurrence.

The analysis compared the effectiveness of more than a dozen antidepressants, showing that while escitalopram had the best outcomes, the differences between medications were modest. Experts caution that this does not mean everyone with severe depression should switch to escitalopram. Each antidepressant has its own benefits and drawbacks, and individual responses can vary widely. According to Prof. Eric Ruhé, one of the researchers, the findings can guide discussions between patients and prescribers about choosing the right medication for long-term health.

Despite the promising results for escitalopram, experts like Dr. Sameer Jauhar and Prof. Allan Young stress that these findings should not prompt patients currently doing well on other medications to change their treatment. The research provides valuable insights but also highlights the need for personalized care in treating depression, as what works best can differ from person to person. Longer studies are still necessary to fully understand the long-term effectiveness of these medications.